PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-23.20%
Both yoy net incomes decline, with GNPX at -129.54%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.49%
Less D&A growth vs. GNPX's 49.36%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
-100.00%
Negative yoy deferred tax while GNPX stands at 100.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
19.58%
SBC growth well above GNPX's 15.96%. Michael Burry would flag major dilution risk vs. competitor’s approach.
19.36%
Less working capital growth vs. GNPX's 481.07%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.56%
Lower AP growth vs. GNPX's 514.91%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-124.52%
Negative yoy usage while GNPX is 233445.70%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
56.31%
Lower 'other non-cash' growth vs. GNPX's 20213300.00%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-16.84%
Both yoy CFO lines are negative, with GNPX at -162.44%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
100.00%
Some CapEx rise while GNPX is negative at -49.31%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have mild expansions while GNPX is negative at -49.31%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-594.74%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.